VanEck Biotech ETF (NASDAQ:BBH) Sees Large Decline in Short Interest

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 1,400 shares, a decline of 17.6% from the December 31st total of 1,700 shares. Based on an average daily volume of 10,800 shares, the short-interest ratio is currently 0.1 days.

VanEck Biotech ETF Price Performance

BBH stock traded up $0.15 during midday trading on Monday, reaching $165.40. The company’s stock had a trading volume of 11,021 shares, compared to its average volume of 11,696. The business’s 50-day simple moving average is $161.97 and its 200-day simple moving average is $170.83. VanEck Biotech ETF has a 52 week low of $151.35 and a 52 week high of $183.64.

VanEck Biotech ETF Dividend Announcement

The business also recently declared a dividend, which was paid on Tuesday, December 24th. Stockholders of record on Monday, December 23rd were given a $1.2517 dividend. The ex-dividend date of this dividend was Monday, December 23rd.

Institutional Investors Weigh In On VanEck Biotech ETF

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Truvestments Capital LLC acquired a new position in shares of VanEck Biotech ETF during the 3rd quarter worth about $44,000. FSA Wealth Management LLC bought a new stake in VanEck Biotech ETF in the third quarter valued at approximately $54,000. Coastline Trust Co acquired a new stake in VanEck Biotech ETF in the third quarter worth $59,000. Wilmington Savings Fund Society FSB bought a new position in shares of VanEck Biotech ETF during the third quarter worth $166,000. Finally, Tyler Stone Wealth Management grew its holdings in shares of VanEck Biotech ETF by 79.5% in the 3rd quarter. Tyler Stone Wealth Management now owns 1,472 shares of the company’s stock valued at $261,000 after buying an additional 652 shares during the period. Institutional investors own 32.05% of the company’s stock.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.